Abstract
Background: Epidermal growth factor receptor (EGFR) mutations are the most clinically actionable oncogenic drivers in Asian patients with non-small-cell lung cancer (NSCLC). The therapeutic landscape has rapidly evolved from single-agent EGFR tyrosine kinase inhibitors (TKIs) to risk-adapted first-line intensi...
R. Meng, Chun-Wei Xu, Wen-Xian Wang et al.· International Open Medical J...· 0 citations
BACKGROUND
Pembrolizumab plus chemotherapy with a platinum-based agent and pemetrexed is a widely used standard first-line treatment option for patients with programmed death ligand 1 (PD-L1)-negative advanced nonsquamous non-small-cell lung cancer (NSCLC) without targetable genomic alterations, but outcomes remain sub...
Fei Zhou, Xiang-Jiao Meng, Qing-Qing Ding et al.· New England Journal of Medic...· 0 citations
Rare tumors constitute a substantial portion of cancer diagnoses, however, research remains limited. To assess the utility of genomic testing for informing treatment decisions, we retrospectively evaluated the landscape of actionable genomic alterations and immune biomarkers in rare tumors. Genomic and clinical data fr...
Guo-Min Lin, Yue Hao, Qian Wang et al.· International Open Medical J...· 0 citations
The current developments in engineering of Cas effector protein, optimizing guide RNA designs, developing advanced reporter probes, and utilizing chemical additives are summarized and their significant contribution to increasing the fidelity of editing and diagnostic sensitivity is highlighted.
Sheng Li, Han Li, Bojie Chen et al.· Interdisciplinary Medicine· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.